BackRadiopharm Theranostics Limited Overview

Radiopharm Theranostics Limited Common Stock

Track Radiopharm Theranostics Limited's common stock ($210M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$209.95M

Peer trimmed avg / median

Loading

Radiopharm Theranostics Limited Common Stock History

Loading

Radiopharm Theranostics Limited vs. peers: Common Stock Comparison

Loading

Radiopharm Theranostics Limited Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

Radiopharm Theranostics Limited (RADX) FAQ

The latest common stock for RADX is $210M as of June 2026. Investors often review this figure alongside Radiopharm Theranostics Limited's historical trend and sector peers before judging valuation or financial health.

A common stock figure of $210M for RADX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting RADX's common stock ($210M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Radiopharm Theranostics Limited's common stock against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.